Research has demonstrated that the human papillomavirus (HPV) vaccine is a safe and
effective way to decrease HPV-related cervical cancers; however, the vaccination rate in the …

Introduction: Human papillomavirus (HPV) vaccination, which is recommended for US
women and girls aged 11–26 years, effectively prevents cervical cancer. Researchers have …

Background Low human papillomavirus (HPV) vaccination rates early after introduction,
particularly among low income and minority adolescents, may have resulted in disparities in …

ABSTRACT In 2018, the Food and Drug Administration expanded the age of eligibility for the
human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are …

Purpose To examine the association between race/ethnicity and human papillomavirus
(HPV) vaccine initiation and to determine how access to health care influences this …

Background Human papillomavirus (HPV) infection and cervical cancer disproportionately
affect low-income and minority women. HPV vaccines have the potential to either reduce or …

If distributed equitably, Human Papillomavirus (HPV) vaccines have the potential to reduce
racial disparities in HPV-related diseases and cervical cancers. However, current trends in …

Introduction Several studies have identified disparities in human papillomavirus (HPV)-
related outcomes by nativity status (ie, US-versus foreign-born). However, few studies have …

Background Overall, foreign-born women are less likely than US-born women to have
initiated human papillomavirus (HPV) vaccination. However, foreign-born women are a …

Background Human papillomavirus (HPV) infection is the most common sexually transmitted
infection (STI) in the United States (US). HPV vaccines have the ability to prevent infection …